GD26 in T-cell lymphomas: A potential clinical role?

ONCOLOGY

Volumn 14, Issue 6 SUPPL. 2, 2000, Pages 17-23

  Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DIPEPTIDYL PEPTIDASE IV; PENTOSTATIN; TUMOR MARKER;

BIOSYNTHESIS; CLASSIFICATION; GENETICS; HUMAN; METABOLISM; MORTALITY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; REVIEW; T CELL LYMPHOMA; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD26; CLINICAL TRIALS, PHASE II; HUMANS; LYMPHOMA, T-CELL; PENTOSTATIN; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034198735     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Harris ML, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.
2. Fisher RI, Miller TP, Grogan TM: New REAL clinical entities. Cancer J Sci Am 4:S5-12, 1998.
3. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.